Jing Lou, CEO of 3SBio. ‘This investment allows 3SBio to gain access to the best external science and small molecule drug discovery system in China.’ ‘Apoptosis targeted small molecule gets the potential to play a key role within the next era of highly effective targeted cancer medications,’ said Dr. Dajun Yang, CEO of Ascentage Pharma. ‘We think that this ‘win-win’ collaboration will generate innovative medications that benefits patients world-wide.’ SOURCE 3SBio Inc.. 3SBio, Ascentage Pharma announce cancer therapeutics collaboration 3SBio Inc. , a respected China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Company, Ltd.To accelerate test advancement cycles, the new equipment are manufactured and quality managed under current good manufacturing procedures and ISO 13485 standards. Additionally, with an instrument system and reagents that are FDA-cleared for in vitro diagnostic make use of and CE-marked as IVD medical devices for sale in europe, the Affymetrix medical toolkit eases the regulatory burden. From a regulatory perspective, developing our standardized microarray-structured AMLprofiler for diagnosing severe myeloid leukemia using Affymetrix instrumentation, reagents, and arrays is vital absolutely, and the IVD reagents are therefore a central component of the product, said Dr.